Document is current
Any future updates will be listed below
-
Authors
Borchert, Grace A.
Charbel Issa, Peter
Xue, Kanmin
MacLaren, Robert E.
Cehajic-Kapetanovic, Jasmina
Downes, Susan M.
De Silva, Samantha R. https://orcid.org/0000-0002-4455-2814
-
Funding
Funding for this research was provided by:
Macular Society
University of Oxford Clarendon-Keble de Breyne
Ramsay Scholarship
NIHR Oxford Biomedical Research Centre
Wellcome Trust
MRC
- License Information
-
More Information
Article History
Received: 16 October 2025
Revised: 15 January 2026
Accepted: 3 February 2026
First Online: 21 February 2026
Declarations
:
: This article does not contain any studies with human participants or animals performed by any of the authors.
: REM and PCI are co-founders of Beacon Therapeutics, a retinal gene therapy company. All other authors certify that they have no affiliations with or involvement in any organisation or entity with any financial interests (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interests (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.
: The authors declare no competing interests.
